Q-omics provides the consensus-scored SNORA53 profile across patient tissues and cancer cell-line models. SNORA53 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SNORA53 is differentially expressed in 7, with the highest sampling consensus in STAD. Additionally, SNORA53 RNA expression shows 10,608 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, STAD, and UVM as cancer lineages where SNORA53 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA53 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA53 survival associations across molecular data types. SNORA53 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA53 RNA expression–survival associations across cancer types. High SNORA53 expression shows unfavorable associations in KIRC, LGG, ACC and THCA, but favorable associations in LIHC and LUAD. The LIHC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SNORA53 RNA expression.
This table summarizes SNORA53 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA53. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA53 shows lower tumor expression in THCA and BRCA and higher tumor expression in STAD, LIHC, COAD and CHOL. The STAD box plot shows higher SNORA53 RNA expression in tumor versus normal tissue (log2 FC = +0.431, t-test p = .005).
This table shows molecular features associated with SNORA53 in patient tissues and cancer cell lines. In patient samples, SNORA53 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
